632 related articles for article (PubMed ID: 11036937)
1. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta acts as a dominant regulator of estrogen signaling.
Pettersson K; Delaunay F; Gustafsson JA
Oncogene; 2000 Oct; 19(43):4970-8. PubMed ID: 11042684
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen agonism and estrogen antagonism of c-fos gene promoter activity through non-consensus-responsive elements in MC3T3-E1 osteoblasts.
Ishibashi O; Yamagishi T; Hanada K; Kawashima H
Biochem Biophys Res Commun; 2001 Dec; 289(3):705-11. PubMed ID: 11726205
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes.
Meyers MJ; Sun J; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA
J Med Chem; 1999 Jul; 42(13):2456-68. PubMed ID: 10395487
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre M; Smith CL
J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
[TBL] [Abstract][Full Text] [Related]
7. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium.
Hunter DS; Hodges LC; Vonier PM; Fuchs-Young R; Gottardis MM; Walker CL
Cancer Res; 1999 Jul; 59(13):3090-9. PubMed ID: 10397250
[TBL] [Abstract][Full Text] [Related]
9. [Anti-estrogens, selective estrogen receptor modulators (SERM), tibolone: modes of action].
Maudelonde T; Brouillet JP; Pujol P
Contracept Fertil Sex; 1999 Sep; 27(9):620-4. PubMed ID: 10540506
[TBL] [Abstract][Full Text] [Related]
10. The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems.
Kuiper GG; Shughrue PJ; Merchenthaler I; Gustafsson JA
Front Neuroendocrinol; 1998 Oct; 19(4):253-86. PubMed ID: 9799586
[TBL] [Abstract][Full Text] [Related]
11. Properties of overlapping EREs: synergistic activation of transcription and cooperative binding of ER.
Massaad C; Coumoul X; Sabbah M; Garlatti M; Redeuilh G; Barouki R
Biochemistry; 1998 Apr; 37(17):6023-32. PubMed ID: 9558340
[TBL] [Abstract][Full Text] [Related]
12. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.
Hall JM; McDonnell DP
Endocrinology; 1999 Dec; 140(12):5566-78. PubMed ID: 10579320
[TBL] [Abstract][Full Text] [Related]
13. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens.
Montano MM; Ekena K; Delage-Mourroux R; Chang W; Martini P; Katzenellenbogen BS
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6947-52. PubMed ID: 10359819
[TBL] [Abstract][Full Text] [Related]
14. Potential benefits of estrogens and progestogens on breast cancer.
Schneider HP; Jackisch C
Int J Fertil Womens Med; 1998; 43(6):278-85. PubMed ID: 9920536
[TBL] [Abstract][Full Text] [Related]
15. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members.
Kraichely DM; Sun J; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 2000 Oct; 141(10):3534-45. PubMed ID: 11014206
[TBL] [Abstract][Full Text] [Related]
16. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist.
Pike AC; Brzozowski AM; Hubbard RE; Bonn T; Thorsell AG; Engström O; Ljunggren J; Gustafsson JA; Carlquist M
EMBO J; 1999 Sep; 18(17):4608-18. PubMed ID: 10469641
[TBL] [Abstract][Full Text] [Related]
17. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer.
Flötotto T; Djahansouzi S; Gläser M; Hanstein B; Niederacher D; Brumm C; Beckmann MW
Horm Metab Res; 2001 Aug; 33(8):451-7. PubMed ID: 11544557
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways.
Katzenellenbogen BS
J Soc Gynecol Investig; 2000; 7(1 Suppl):S33-7. PubMed ID: 10732327
[TBL] [Abstract][Full Text] [Related]
19. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens.
Fink BE; Mortensen DS; Stauffer SR; Aron ZD; Katzenellenbogen JA
Chem Biol; 1999 Apr; 6(4):205-19. PubMed ID: 10099132
[TBL] [Abstract][Full Text] [Related]
20. The biological significance of the interaction of estrogen agonists and antagonists with the estrogen receptor.
Murphy CS; Jordan VC
Receptor; 1990-1991 Winter; 1(1-2):65-82. PubMed ID: 2152373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
